Guanidines: From molecule to primate

D. W. Oliver; I. C. Dormehl; J. E.S. Wikberg; M. Dambrova

doi:10.1007/s00044-004-0046-2

Guanidines: From molecule to primate

D. W. Oliver, I. C. Dormehl, J. E.S. Wikberg, M. Dambrova

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Guanidine-like compounds have been investigated since the first observations of their therapeutic potential some 30 years ago in fields of cancer and virology. Guanidine-type compounds that reached clinical status include amongst others the potassium channel opener, pinacidil and the histamine H₂-receptor antagonists (e.g. cimetidine). Recent research on guanidines has focused on enzyme systems such as xanthine oxidase and nitric oxide synthase. Our studies demonstrated an in vivo cardioprotection effect of (N-(3,4,-dimethoxy-2-chlorobenzylideneamino)-guanidine: ME10092) in ischaemic reperfusion injury in the rodent. The present investigation in the normal non-human primate, Papio ursinus baboons showed cardiovascular negative chronotropic effects and transient decreases in blood pressure, which correspond to those observed in the in vivo cardioprotection studies in the rodent.

Original language	English
Pages (from-to)	427-438
Number of pages	12
Journal	Medicinal Chemistry Research
Volume	13
Issue number	6-7
DOIs	https://doi.org/10.1007/s00044-004-0046-2
Publication status	Published - 2004
Externally published	Yes

Field of Science*

1.4 Chemical sciences
3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00044-004-0046-2

Cite this

@article{62c8e69f1b7c4980843e38935e77c962,

title = "Guanidines: From molecule to primate",

abstract = "Guanidine-like compounds have been investigated since the first observations of their therapeutic potential some 30 years ago in fields of cancer and virology. Guanidine-type compounds that reached clinical status include amongst others the potassium channel opener, pinacidil and the histamine H2-receptor antagonists (e.g. cimetidine). Recent research on guanidines has focused on enzyme systems such as xanthine oxidase and nitric oxide synthase. Our studies demonstrated an in vivo cardioprotection effect of (N-(3,4,-dimethoxy-2-chlorobenzylideneamino)-guanidine: ME10092) in ischaemic reperfusion injury in the rodent. The present investigation in the normal non-human primate, Papio ursinus baboons showed cardiovascular negative chronotropic effects and transient decreases in blood pressure, which correspond to those observed in the in vivo cardioprotection studies in the rodent.",

author = "Oliver, {D. W.} and Dormehl, {I. C.} and Wikberg, {J. E.S.} and M. Dambrova",

year = "2004",

doi = "10.1007/s00044-004-0046-2",

language = "English",

volume = "13",

pages = "427--438",

journal = "Medicinal Chemistry Research",

issn = "1054-2523",

publisher = "Birkhauser Boston",

number = "6-7",

}

TY - JOUR

T1 - Guanidines

T2 - From molecule to primate

AU - Oliver, D. W.

AU - Dormehl, I. C.

AU - Wikberg, J. E.S.

AU - Dambrova, M.

PY - 2004

Y1 - 2004

N2 - Guanidine-like compounds have been investigated since the first observations of their therapeutic potential some 30 years ago in fields of cancer and virology. Guanidine-type compounds that reached clinical status include amongst others the potassium channel opener, pinacidil and the histamine H2-receptor antagonists (e.g. cimetidine). Recent research on guanidines has focused on enzyme systems such as xanthine oxidase and nitric oxide synthase. Our studies demonstrated an in vivo cardioprotection effect of (N-(3,4,-dimethoxy-2-chlorobenzylideneamino)-guanidine: ME10092) in ischaemic reperfusion injury in the rodent. The present investigation in the normal non-human primate, Papio ursinus baboons showed cardiovascular negative chronotropic effects and transient decreases in blood pressure, which correspond to those observed in the in vivo cardioprotection studies in the rodent.

AB - Guanidine-like compounds have been investigated since the first observations of their therapeutic potential some 30 years ago in fields of cancer and virology. Guanidine-type compounds that reached clinical status include amongst others the potassium channel opener, pinacidil and the histamine H2-receptor antagonists (e.g. cimetidine). Recent research on guanidines has focused on enzyme systems such as xanthine oxidase and nitric oxide synthase. Our studies demonstrated an in vivo cardioprotection effect of (N-(3,4,-dimethoxy-2-chlorobenzylideneamino)-guanidine: ME10092) in ischaemic reperfusion injury in the rodent. The present investigation in the normal non-human primate, Papio ursinus baboons showed cardiovascular negative chronotropic effects and transient decreases in blood pressure, which correspond to those observed in the in vivo cardioprotection studies in the rodent.

UR - http://www.scopus.com/inward/record.url?scp=20344407081&partnerID=8YFLogxK

U2 - 10.1007/s00044-004-0046-2

DO - 10.1007/s00044-004-0046-2

M3 - Article

AN - SCOPUS:20344407081

SN - 1054-2523

VL - 13

SP - 427

EP - 438

JO - Medicinal Chemistry Research

JF - Medicinal Chemistry Research

IS - 6-7

ER -

Guanidines: From molecule to primate

Abstract

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this